Researchers from the Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated from the RTS,S malaria vaccine--work that could boost the development of a more potent vaccine against the global killer.
In a study published this week in the journal Proceedings of the National Academy of Sciences, the researchers provide an atomic-level view of how human antibodies bind to an important malarial surface protein, the circumsporozoite protein (CSP), to protect against the malaria parasite. These new structures could potentially help scientists enhance RTS,S efficacy and duration, the world's most advanced malaria vaccine to date, which has shown partial protection against the disease in a large-scale Phase 3 clinical trial.
The RTS,S vaccine was the outcome of a long-standing collaboration between PATH and GSK that began in 2001 and involved research institutions in Africa and worldwide. RTS,S is the first and, to date, the only vaccine to show a protective effect against malaria among young children in Phase 3 clinical trials.
Efforts continue to enhance the vaccine's efficacy and duration of protection against malaria, a major public health problem that infects millions of people each year. An estimated 429,000 people died from the mosquito-borne illness in 2015 and 212 million people were infected.
In this study, the investigators structurally characterized antibodies to CSP produced in response to a delayed fractional dose trial (MAL071) of the RTS,S-vaccine. Ian Wilson, D.Sc., the Hansen Professor of Structural Biology at TSRI, led the study. David Oyen, PhD, a research associate in Wilson's lab, is the first author. The antibodies were discovered from the protected vaccines by scientists at Atreca, a biotech company that worked in the collaboration.
"In order to design a next-generation vaccine, you need to know first the atomic details of highly protective antibody interaction," said Oyen. "Specifically, you need to know what part of the elicited antibodies recognizes what part of the malaria antigen."
"What Oyen and Wilson have done, together with the other collaborators, is to give us a very detailed picture of how those antibodies do the business of rejecting the (malaria) parasite, and that's very important," said Rick King, PhD, MVI's director of research and development and a co-author on the study. "This information will be very useful as we work to modify the existing vaccine so that it can be more protective."
In their study, Wilson and colleagues used X-ray crystallography and other sophisticated imaging technologies to analyze how two functional antibodies from RTS,S-vaccinated individuals latched onto the CSP protein target.
TSRI Professor Andrew Ward, PhD, a co-author whose lab provided electron microscopy expertise, said the researchers created structural images of the antibody binding to determine the precise area the immune system goes after.
"We were looking at what piece of the (CSP) protein the antibody is targeting," Ward said. "If we can focus the immune response on the real Achilles heel, the sites of vulnerability on the CSP protein, we would hope to get a more effective vaccine response."
The researchers drilled down to how the antibodies recognized the immunodominant NANP repeats within CSP, considered the area most important for eliciting a strong immune response and the basis for the RTS,S vaccine.
The research team pinpointed the number of NANP repeats that interacted with the two antibody fragments and established how the antibodies bind to the NANP repeat region.
"We found that these antibodies bind certain elements of the repeat peptides in a similar way," said Wilson, noting this information could be useful in engineering a next-generation vaccine. "The goal is to direct the immune system towards a particular region of the malaria pathogen surface protein to produce the type of antibodies that you know are or have a good possibility of being protective."
With this new structural map, the scientists have a better understanding of where the vaccine needs to be stabilized to better mimic CSP and "teach" the immune system to target malaria.
In addition to Wilson, Oyen, Ward, and King, other co-authors on the study, "Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein," were Jonathan L. Torres of TSRI; Ulrike Wille-Reece and Christian Ockenhouse of PATH's Malaria Vaccine Initiative; Daniel Emerling, Wayne Volkmuth of Atreca Inc.; Jacob Glanville of Stanford University; Yevel Flores-Garcia, Fidel Zavala, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health.
The study was supported by PATH's Malaria Vaccine Initiative under a collaborative agreement with TSRI.
Source: Scripps Research Institute
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.